Needham analyst Serge Belanger assigned a Buy rating to Aerie Pharma (AERI – Research Report) today and set a price target of $26.00. The company’s shares closed last Thursday at $11.64, close to its 52-week low of $10.22.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.4% and a 35.2% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $27.50, a 144.1% upside from current levels. In a report issued on September 12, Mizuho Securities also maintained a Buy rating on the stock with a $27.00 price target.
Based on Aerie Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $20.34 million and GAAP net loss of $49.13 million. In comparison, last year the company earned revenue of $15.84 million and had a GAAP net loss of $47.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.